Karcher J, Reisser C, Daniel V, Herold-Mende C
Universitäts-HNO-Klinik Heidelberg.
HNO. 1999 Oct;47(10):879-84. doi: 10.1007/s001060050528.
Transforming growth factor-beta (TGF-beta) and interleukin 10 (Il-10) are cytokines that have a strong immunosuppressive ability. Their secretion by tumor cells is able to suppress an immunological response against tumor. Both factors have been shown to enhance tumor growth in glioblastomas and carcinoma of the breast. We determined the expression pattern of TGF-beta and Il-10 in squamous cell carcinomas of the head and neck (HNSCC) and a possible association with tumor stage and their pre-treatment cytokine serum levels. Cytokine expression in primary tumors and metastases of 21 patients with HNSCC was investigated by immunohistochemistry. To assess the TGF-beta2 and Il-10 levels in tumor patients before therapy 49 serum specimens were analyzed by ELISA. TGF-beta2 was detected in 95% of all tumor tissues analyzed and Il-10 in 79% of all tumors. TGF-beta2 was localized in tumor cells and tumor borders, while Il-10 was preferentially found in peritumoral connective tissue. Metastasizing tumors showed elevated pretreatment serum levels for TGF-beta2 and Il-10. There was no correlation between TGF-beta2 and Il-10 expression in tumor tissue and pretreatment serum levels. Our data show that the majority of HNSCC analyzed express TGF-beta2 and Il-10. A correlation between pretherapy elevated cytokine serum levels and tumor grade was shown.
转化生长因子-β（TGF-β）和白细胞介素10（IL-10）是具有强大免疫抑制能力的细胞因子。肿瘤细胞分泌这些因子能够抑制针对肿瘤的免疫反应。在胶质母细胞瘤和乳腺癌中，这两种因子均已被证明可促进肿瘤生长。我们确定了头颈部鳞状细胞癌（HNSCC）中TGF-β和IL-10的表达模式，以及它们与肿瘤分期及其治疗前细胞因子血清水平之间可能存在的关联。通过免疫组织化学研究了21例HNSCC患者原发肿瘤和转移灶中的细胞因子表达情况。为评估肿瘤患者治疗前的TGF-β2和IL-10水平，采用酶联免疫吸附测定（ELISA）法分析了49份血清标本。在所有分析的肿瘤组织中，95%检测到TGF-β2，79%检测到IL-10。TGF-β2定位于肿瘤细胞和肿瘤边界，而IL-10则优先在肿瘤周围结缔组织中发现。发生转移的肿瘤在治疗前血清中TGF-β2和IL-10水平升高。肿瘤组织中TGF-β2和IL-10的表达与治疗前血清水平之间无相关性。我们的数据表明，大多数分析的HNSCC表达TGF-β2和IL-10。结果显示治疗前细胞因子血清水平升高与肿瘤分级之间存在相关性。
